Saturday 17 October 2026
Export BRKR’s income statement to Excel — free account
Bruker Corporation
BRKR Healthcare Medical Devices
Bruker Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.4 billion, up 2.08% from fiscal 2024. In the quarter to June 2026, revenue grew 5.15%, EPS fell 920.0%, free cash flow grew 28.6% and total debt fell 25.1%, each against the same quarter a year earlier. Dividend growth for ten consecutive years, revenue growth for five.
54.80
1.74
−3.08%
Follow BRKR
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
2.62 | 1.59 | 2.08 | 1.43 | |
P/FCF ratio |
77.21 | 72.24 | 105.01 | 347.32 | |
P/Operating CF |
(118.42) | 77.21 | 31.12 | (148.55) | |
P/B ratio |
3.82 | 2.23 | 2.89 | 2.01 | |
Price to Tangible BV |
89.33 | 0.00 | 272.95 | 0.00 | |
EV/Sales |
3.09 | 2.03 | 2.54 | 1.93 | |
EV/EBITDA |
54.16 | 25.60 | 30.23 | 23.82 | |
EV/Operating CF |
56.75 | 50.15 | 65.04 | 70.49 | |
EV/FCF |
91.03 | 92.45 | 128.07 | 468.13 | |
Quick Ratio |
0.61 | 0.50 | 0.66 | 0.67 | |
Current Ratio |
1.85 | 1.55 | 1.73 | 1.85 | |
Net Debt/EBITDA |
(224.64) | 22.45 | 11.68 | 439.85 | |
Debt/Assets |
30.15% | 27.26% | 29.95% | 31.21% | |
Debt/Equity |
0.76 | 0.68 | 0.76 | 0.82 | |
Asset Turnover |
0.56 | 0.57 | 0.57 | 0.55 | |
Operating CF/Net income |
1.23 | 20.34 | 15.42 | 0.53 | |
Capex/Depreciation |
(0.50) | (0.42) | (0.39) | (0.38) | |
Research and Development Expense of Revenue |
11.25% | 12.30% | 10.19% | 11.42% | |
Selling, General and Administrative Expense of Revenue |
28.49% | 29.40% | 25.30% | 28.18% | |
Intangible Assets out of Total Assets |
0.38 | 0.40 | 0.39 | 0.38 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 2.07% | 0.00% | |
Graham Net Nets |
(0.16) | (0.28) | (0.22) | (0.33) | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(1.16%) | (0.66%) | (0.32%) | (0.49%) | |
Free Cash Flow Yield |
1.30% | 1.38% | 0.95% | 0.29% | |
Revenue per Share |
5.51 | 5.41 | 6.44 | 5.67 | |
Operating CF per Share |
(0.51) | 0.47 | 1.51 | (0.22) | |
Capex per Share |
(0.19) | (0.16) | (0.15) | (0.14) | |
Free Cash Flow per Share |
(0.70) | 0.31 | 1.37 | (0.36) | |
Cash per Share |
1.21 | 0.88 | 1.97 | 1.93 | |
Shareholders Equity per Share |
15.76 | 16.21 | 16.29 | 16.14 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
15.76 | 16.21 | 16.29 | 16.14 | |
Free Cash Flow |
(106.20) | 47.00 | 207.20 | (54.10) | |
Working Capital |
1,020.30 | 748.50 | 933.30 | 1,082.50 | |
Capital Expenditures |
(28.80) | (24.20) | (22.60) | (20.90) | |
Net Current Asset Value |
(1,427.70) | (1,560.10) | (1,555.40) | (1,634.80) | |
EV/EBIT |
0.00 | 150.97 | 127.88 | 103.87 | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.02 | |
Price to Operating Income |
0.00 | 117.97 | 104.86 | 77.06 | |
| Other line items | |||||
Average Receivables |
534.25 | 540.25 | 555.20 | 544.65 | |
Average Payables |
221.60 | 256.85 | 225.00 | 205.95 | |
Average Inventory |
1,169.20 | 1,119.00 | 1,081.20 | 1,208.50 | |
Average Assets |
6,196.35 | 6,031.90 | 6,024.05 | 6,273.90 | |
Average Common Equity |
2,109.80 | 2,149.95 | 2,135.30 | 2,137.30 |
Columns are period end dates